there is still an expectation of some pretty high premiums in the market," he said. The CEO said Biogen has "teams of people" at the healthcare conference this week. At last year's meeting, those ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...